Symphony Financial Services Inc. Sells 1,552 Shares of Novo Nordisk A/S $NVO

Symphony Financial Services Inc. decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 22.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,371 shares of the company’s stock after selling 1,552 shares during the quarter. Symphony Financial Services Inc.’s holdings in Novo Nordisk A/S were worth $370,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Stone House Investment Management LLC purchased a new position in shares of Novo Nordisk A/S in the 1st quarter worth about $30,000. NewSquare Capital LLC increased its stake in Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares in the last quarter. Disciplina Capital Management LLC raised its holdings in Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 297 shares during the last quarter. Dagco Inc. bought a new position in shares of Novo Nordisk A/S in the first quarter worth approximately $35,000. Finally, Mid American Wealth Advisory Group Inc. purchased a new stake in shares of Novo Nordisk A/S during the second quarter valued at approximately $37,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Up 7.1%

NYSE NVO opened at $49.21 on Wednesday. The stock’s 50-day moving average price is $54.96 and its 200-day moving average price is $61.30. The company has a market capitalization of $219.72 billion, a P/E ratio of 13.52, a price-to-earnings-growth ratio of 2.33 and a beta of 0.65. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The company had revenue of $11.74 billion for the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Morgan Stanley lowered shares of Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and decreased their price objective for the stock from $59.00 to $47.00 in a report on Monday, September 29th. Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, November 5th. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. TD Cowen decreased their target price on Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, August 19th. Finally, BNP Paribas Exane upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price on the stock in a research note on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus price target of $59.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.